READ MORE AVELOX LEGAL NEWS
According to the report, Avelox, known generically as moxifloxacin, "penetrates well into inflammatory blister fluid, muscle and subcutaneous adipose tissues," which makes it a potential treatment option.The study reportedly used a rat burn infection model and examined 14-day follow-up samples to determine that the treatment was effective, according to the organization. The report was published online on February 22 ahead of its print publication.
"The use of topical antibiotics for the treatment of infected wounds confers many benefits," the researchers said. "Moxifloxacin is therefore an ideal candidate, due to its broad antibacterial spectrum, its high efficiency and its potential to promote wound healing."
While Avelox may be shown to be effective in treating infected skin wounds, certain side effects of the drug can include the development of tendinitis or even tendon rupture, according to the National Center for Biotechnology Information.
READER COMMENTS
mr. david t fuller
on
antibiotics, authorised for a wide range of indications. Those currently authorised in
Ireland include: moxifloxacin, levofloxacin, ofloxacin and ciprofloxacin*. The potential for fluoroquinolones to cause QT prolongation is recognised and has been previously considered on the basis of available data for the individual substances, as reflected in the product specific information.
A further recent European review of study and postmarketing data in relation to QT prolongation and fluoroquinolones concluded that the risk of QT prolongation does not appear to be similar across this class of antibiotics, but that substances may be classified according to their potential to prolong QT interval and precipitate cardiac events (i.e. ventricular arrhythmia). As moxifloxacin has been associated with an
established potential for increased risk of QT prolongation, prescribers are reminded to use moxifloxacin only when it is considered inappropriate to use antibacterial agents that are commonly recommended or when these have failed for the treatment of: acute bacterial sinusitis, acute exacerbations of chronic bronchitis, community acquired pneumonia (except severe cases) and mild to moderate pelvic inflammatory disease.
Following assessment of the available evidence, levofloxacin, ofloxacin and ciprofloxacin are considered to have a lower potential to induce QT interval prolongation. It is important to note that in the context of conditions which favour the development of QT prolongation e.g. hypokalaemia, hypomagnesaemia,
bradycardia, patients with congenital or acquired QT prolongation, some fluoroquinolones have the potential to induce life-threatening Torsades de Pointes (e.g. moxifloxacin).
The product information for fluoroquinolones will be updated and harmonised throughout Europe in relation to the updated assessment of the risk of QT interval prolongation for the individual substances. For further information and the complete list of fluoroquinolones considered as part of the review please see the following link:
http://www.ema.europa.eu/docs/en_GB/document_library/Report/2011/01/WC500100459.pdf
Key Message:
• The risk of QT interval prolongation with fluoroquinolone antibiotics varies across the
class
• Due to an increased risk of QT prolongation (in addition to the potential for other serious
risks, i.e. serious hepatotoxicity), oral moxifloxacin should only be used when use
of other antibacterial agents is inappropriate, or have failed.
• Consideration should be given to official guidance on the appropriate use of antibacterial
agents.
* Brands include: Moxifloxacin – Avelox Levofloxacin – Tavanic, Tavager Ofloxacin - Tarivid, Biravid Ciprofloxacin – Truoxin, Ciproxin
see: http://tinyurl.com/4hyr3t3